Evaluation of a One-step Dose Reduction Strategy for Adalimumab, Etanercept and Ustekinumab in Patients with Psoriasis in Daily Practice

Psoriasis

Biological treatments for paediatric psoriasis (BiPe): A retrospective observational study on biological drug survival in daily practice in childhood psoriasis

J Eur Acad Dermatol Venereol.

Phan C, Beauchet A, Burztejn AC, Severino-Freire M, Barbarot S, Girard C, Lasek A, Reguiai Z, Hadj-Rabia S, Abasq C, Brenaut E, Droitcourt C, Perrussel M, Mallet S, Phan A, Lacour JP, Khemis A, Bourrat E, Chaby G, Deborde R, Plantin P, Maruani A, Piram M, Maccari F, Fougerousse AC, Kupfer-Bessaguet I, Balguérie X, Barthelemy H, Martin L, Quiles-Tsimaratos N, Mery-Brossard L, Pallure V, Lons-Danic D, Bouilly-Auvray D, Beylot-Barry M, Puzenat E, Aubin F, Mahé E E, Groupe de Recherche de la Société Française de Dermatologie Pédiatrique, Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie

doi: 10.1111/jdv.15579.

Rheumatoid Arthritis

Effectiveness and healthcare costs among stabilised rheumatoid arthritis patients with dose reduction of adalimumab or etanercept in real world.

Clin Exp Rheumatol.

Yang M, Galebach PJ, Signorovitch JE, Garg V

Psoriasis

Comparison of Tightly Controlled Dose Reduction of Biologics With Usual Care for Patients With Psoriasis: A Randomized Clinical Trial

JAMA Dermatol.

Atalay S, van den Reek JMPA, den Broeder AA, van Vugt LJ, Otero ME, Njoo MD, Mommers JM, Ossenkoppele PM, Koetsier MI, Berends MA, van de Kerkhof PCM, Groenewoud HMM, Kievit W, de Jong EMGJ

doi: 10.1001/jamadermatol.2019.4897.

Psoriasis

Comparison of Adalimumab and Etanercept for the Treatment of Moderate to Severe Psoriasis: An Indirect Comparison Using Individual Patient Data from Randomized Trials

Value Health.

Papp KA, Yang M, Sundaram M, Jarvis J, Betts KA, Bao Y, Signorovitch JE

doi: 10.1016/j.jval.2017.05.025.

Psoriasis

Drug Survival of Adalimumab, Ustekinumab, and Secukinumab in Patients with Psoriasis: a Prospective Cohort Study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)

Br J Dermatol.

Yiu ZZN, Mason KJ, Hampton PJ, Reynolds NJ, Smith CH, Lunt M, Griffiths CEM, Warren RB, BADBIR Study Group.

doi: 10.1111/bjd.18981.

Psoriasis

Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in pediatric patients (≥6 to < 12 years of age): efficacy, safety, pharmacokinetic, and biomarker results from the open-label CADMUS Jr study

Br J Dermatol.

Philipp S, Menter A, Nikkels AF, Barber K, Landells I, Eichenfield LF, Song M, Randazzo B, Li S, Hsu MC, Zhu Y, DePrimo S, Paller AS

doi: 10.1111/bjd.19018.

COMMENTED

Acne

Adalimumab Medium-Term Dosing Strategy in Moderate-to-Severe Hidradenitis Suppurativa: Integrated Results from the Phase 3, Randomized, Placebo-Controlled, PIONEER Trials

Br J Dermatol.

Jemec GBE, Okun MM, Forman SB, Gulliver WPF, Prens EP, Mrowietz U, Armstrong AW, Geng Z, Gu Y, Williams DA, Teixeira HD, Kimball AB

doi: 10.1111/bjd.17919.

Rheumatoid Arthritis

Therapeutic strategy for Rheumatoid Arthritis Patients who have achieved Remission

Joint Bone Spine.

Fautrel B

doi: 10.1016/j.jbspin.2018.02.002.

Psoriatic Arthritis

Long-term etanercept survival in patients with psoriatic arthritis: a multicenter retrospective analysis in daily clinical practice in Spain

Rheumatol Int.

Deza G, Notario J, Ferran M, Beltrán E, Almirall M, Alcalá R, Ruiz-Carrascosa JC, Sánchez R, Pérez S, García-Vivar ML, Galíndez E, Mora M, Rodríguez J, Gallardo F

doi: 10.1007/s00296-018-4144-8.

Related content

Biological treatments for paediatric psoriasis (BiPe): A retrospective observational study on biological drug survival in daily practice in childhood psoriasis

Effectiveness and healthcare costs among stabilised rheumatoid arthritis patients with dose reduction of adalimumab or etanercept in real world.

Comparison of Tightly Controlled Dose Reduction of Biologics With Usual Care for Patients With Psoriasis: A Randomized Clinical Trial

Comparison of Adalimumab and Etanercept for the Treatment of Moderate to Severe Psoriasis: An Indirect Comparison Using Individual Patient Data from Randomized Trials

Drug Survival of Adalimumab, Ustekinumab, and Secukinumab in Patients with Psoriasis: a Prospective Cohort Study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)

Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in pediatric patients (≥6 to < 12 years of age): efficacy, safety, pharmacokinetic, and biomarker results from the open-label CADMUS Jr study

Adalimumab Medium-Term Dosing Strategy in Moderate-to-Severe Hidradenitis Suppurativa: Integrated Results from the Phase 3, Randomized, Placebo-Controlled, PIONEER Trials

Therapeutic strategy for Rheumatoid Arthritis Patients who have achieved Remission

Long-term etanercept survival in patients with psoriatic arthritis: a multicenter retrospective analysis in daily clinical practice in Spain